Methods
Twenty consecutive patients with polysomnography-confirmed iRBD and no clinical evidence of parkinsonism and cognitive impairment were recruited between March 2015 and October 2016 in our tertiary sleep centres in Spain (Barcelona) and Denmark (Aarhus). We assessed levels of microglial activation in the substantia nigra, putamen, and caudate using 11 C-PK11195 PET and dopamine terminal function in putamen and caudate with 18 F-DOPA PET. Nineteen healthy controls underwent either 11 C-PK11195 PET (n=10) or 18 F-DOPA PET (n=9) for comparison. 
Funding
The study was funded by the Danish Council for Independent
Research and the Spanish Instituto de Salud Carlos III. Available data indicate that the idiopathic form of RBD (iRBD) precedes the development of PD, DLB, and much more rarely MSA. [4] [5] [6] Prospective studies of iRBD patients show a risk of 41% for progression to PD or DLB within 5 years from iRBD diagnosis (cohort size n=279), and up to 91% by 14 years (cohort size n=174). 4 Imaging studies in iRBD patients have detected findings similar to those observed in patients with established PD and DLB such as impaired integrity of the dopaminergic nigrostriatal pathway. [7] [8] [9] Additionally, Lewy type pathology, a neuropathological hallmark of PD and DLB, has been observed in the brains of iRBD cases. 10, 11 Neuroinflammation, a possible disease-causing mechanism that is present in patients manifesting synucleinopathies has not been investigated in iRBD with in vivo molecular imaging.
Using 11 C-PK11195 positron emission tomography (PET), an in vivo marker of microglial activation, several studies have shown increased brain signal in manifest PD, DLB, and MSA. [12] [13] [14] [15] Microglia are the resident immune cells of the central nervous system, and account for the intrinsic inflammatory response to neuronal damage. It is thought that protracted activation of microglia cells may contribute to the development and progression of the neurodegenerative process. 16 Modulation of microglial activation could provide a potential therapeutic strategy for slowing disease progression, particularly in its earliest stages. [17] [18] [19] [20] The objective of this in vivo PET imaging study was to examine the hypothesis that patients with iRBD show increased nigrostriatal levels of activated microglia as part of the neuropathological process. Additionally, we aimed to investigate the relationship between neuroinflammation and dopaminergic function in nigrostriatal structures in iRBD patients.
Methods

Study population
This prospective case-control study was conducted between [18] [19] [20] None of the patients had motor or cognitive complaints. A healthy control group consisting of nineteen subjects who had no motor or cognitive complaints, a normal neurological examination, and a mean group age similar to the iRBD group were recruited to participate in the current study through newspaper advertisements (44 subjects responded, the first eligible subjects were included). They were randomly selected to receive either 11 C-PK11195 PET (n=10) or 18 F-DOPA PET (n=9). Absence of RBD symptoms in the controls was screened by a questionnaire 21 , and a comprehensive clinical history of the individuals and their bed-partner. None of the included subjects were regular users of anti-inflammatory drugs or were taking antidepressants at the time of this study.
The study received approval from the local Ethics Committee at both centers. All subjects gave informed written consent according to the Declaration of Helsinki before enrolment into the study.
PET and MRI imaging
All subjects had PET imaging at the Department of Nuclear Parametric images of 18 F-DOPA influx constants (Ki) ( Figure 1) were generated with the Patlak graphical approach 23 using occipital lobe grey matter as a non-specific reference tissue input function. 24 See online appendix for details on MRI and PET images co-registration and normalisation.
A threshold for abnormality in regional 11 C-PK11195 binding and 
Role of the funding source
The funding source had no influence on the study design, collection, analysis and interpretation of data, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Demographics and clinical characteristics of iRBD patients and controls are reported in Table 1 . There were no differences in age between patients and controls. No adverse events occurred during the study.
iRBD group showed no differences in mean 11 Table 2 ).
Individual analysis showed that 7/20 (35%) iRBD patients had abnormally raised 11 C-PK11195 binding in the substantia nigra, and 2/20 (10%) in the putamen and caudate nucleus (Table 3) .
One subject had bilateral abnormal binding in all three regions investigated; substantia nigra, putamen, and caudate nucleus. to 0003], p=01)( Table 2) .
At an individual level, 18/20 (90%) iRBD patients had abnormally reduced 18 F-DOPA uptake in the putamen in one or both sides and 7/20 (35%) patients had reduced 18 F-DOPA uptake in the caudate nucleus (Table 3 ). All seven patients with reduced 18 F-DOPA uptake in the caudate nucleus also had reduced 13 putaminal uptake ipsilaterally. Six of these seven patients had bilateral abnormally reduced uptake throughout the striatum.
In the iRBD cohort, increased 11 The current study showed a larger degree of neuroinflammation in the substantia nigra than the striatum in iRBD patients.
This was the case for both the group level analysis and on an individual level where 7/20 (35%) subjects had raised 11 C-PK11195 binding in the substantia nigra compared to 2/20 (10%) subjects in the putamen and caudate nucleus (Table 3) . Significantly decreased levels of 18 F-DOPA uptake were found in the putamen of our iRBD patients. This supports findings of previous studies investigating iRBD patients, using ligands for the dopamine transporter (DaT) to measure the integrity of nigrostriatal dopaminergic function. 8, [27] [28] [29] [30] In our analysis of individual subjects 18/20 (90%) had reduced putaminal 18 F-DOPA uptake on at least one side and 14/20 (70%) bilaterally (Table   3 ). This represents a higher frequency of patients with a dopaminergic decrement than that reported across the majority putaminal reduction contralateral to the non-affected limbs and a 43-52% decrease contralateral to the affected limbs. 33 At the group-level, we observed no reduction of mean 18 F-DOPA uptake in the caudate nucleus. This is in line with the fact that dopaminergic function remains relatively preserved in the caudate nucleus when compared with the putamen in patients with early PD. 34 However, some individual subjects were noted to have a decrement in the caudate, which also has been observed in DaT-SPECT studies by others. 8, 29, 30 Currently, it is unknown if a greater reduction in 18 F-DOPA uptake in the caudate nucleus and putamen in individual subjects is a shortterm marker for conversion towards a specific type of synucleinopathy.
We found a significant correlation between raised 11 C-PK11195 binding in the substantia nigra and reduced 18 F-DOPA uptake in the ipsilateral caudate nucleus. This finding might relate to potential progression in some of our cases to DLB, where a more pronounced involvement of the caudate nucleus is observed. 35 We did not find any significant correlations between raised 11 C-PK11195 binding in the substantia nigra or the putamen and reduced 18 F-DOPA uptake in the ipsilateral putamen ( Figure   2C+D ). This accord with similar observations between 11 C-PK11195 and 18 F-DOPA within nigrostriatal structures in patients with PD. 12 Interestingly, while abnormally raised levels of microglial activation in the substantia nigra were only seen in a subgroup 7/20(35%) of our iRBD patients, we found all these patients to have reduced 18 F-DOPA uptake in the ipsilateral putamen. Recent reports have suggested that impaired intracellular trafficking, including dopamine function in the terminals may be an early abnormal phenomenon occurring in PD development. 36, 37 This assumption might explain our observation of reduced putaminal 18 F-DOPA uptake in the absence of detectable nigral microglial activation in some iRBD patients.
The pathogenesis of PD is complex involving a variety of genetic, environmental, cellular, and molecular factors.
There is mounting evidence that the immune system plays an important role since microglial and also astroglial activation are present and have a deleterious effect on neuronal function. 38 Moreover, epidemiologic studies have shown reduced risk of developing PD in users of non-aspirin non-steroidal anti-inflammatory drugs 39 and pharmacological immunosuppression can reduce neurodegeneration in rodent models of PD. 40 Consequently individuals. This is an issue with the newer tracers where exclusion of patients with low or mixed-affinity binding can potentially lead to a selection bias. We acknowledge, however, that 11 C-PK11195 provides a lower specific to background signal ratio than newer microglial markers and our results might underestimate the true extent of microglia activation, particularly in the case of subtle increases. Another possible limitation of the study is that the healthy controls were self-referred as they responded to newspaper advertisements.
However, they had to fulfil all the inclusion/exclusion criteria and they were randomly selected to receive either 11 C-PK11195 PET or 18 F-DOPA PET.
Finally, in this study we have assumed that a raised level of microglial activation is pathogenic. This assumption is at variance with a recent published study in early Alzheimer's disease where it was reported that raised microglial activation appeared to have a protective effect. 41 Longitudinal follow-up of our iRBD individuals will reveal the clinical significance of the current observations. In summary, we have shown that raised microglial activation in the substantia nigra and reduced presynaptic nigrostriatal dopaminergic function can be detected in iRBD patients using a combination of 11 Tables   Table 1 Characteristics and demographics of study population Data are mean (standard deviation) or n (%). iRBD = idiopathic REM sleep behaviour disorder. (-0·002 to 0·0003)
0·1
Mean tracer uptake (BP ND or Ki values) and standard deviation (SD) and mean difference with 95% confidence interval (95% CI). iRBD = idiopathic REM sleep behaviour disorder.
Table 3
Number of iRBD patients with abnormal 11 C-PK11195 BP ND and 18 F-
DOPA Ki values
Added value of this study
This is the first study in iRBD patients using in vivo PET imaging to investigate the occurrence of intrinsic neuroinflammation in the nigrostriatal system, a potential pathological mechanism contributing to the progression towards full-blown synucleinopathies. 11 C-PK11195 PET, a marker of microglial activation, and 18 F-DOPA PET, a marker of dopa decarboxylase activity, were used to investigate levels of nigrostriatal neuroinflammation and dopaminergic nigrostriatal function in iRBD patients, respectively. Significantly increased levels of microglial activation were found in the substantia nigra of iRBD patients. This was correlated with increased levels of microglia activation in the ipsilateral putamen. Additionally, we found decreased 18 F-DOPA uptake in the putamen bilaterally in the iRBD patients compared to controls.
Implications of all available evidence
This study presents the first in vivo observations indicating that increased microglial activation in iRBD is an early component in the neurodegenerative process along with nigrostriatal dopaminergic deficits. This finding marks microglial cells as a potential therapeutic target for future disease-modifying strategies, which could be tested to halt or delay progression of the underlying neurodegenerative process.
Future follow-up studies may elucidate whether high levels of microglial activation are associated with a more rapid progression towards full-blown synucleinopathies and whether these imaging modalities are useful to monitor the effect of disease-modifying strategies.
